Allogeneic stem-cell transplantation in patients with waldenström macroglobulinemia: Report from the lymphoma working party of the european group for blood and marrow transplantation

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4926-4934

  Kyriakou, Charalampia ^a   Canals, Carmen ^a   Cornelissen, Jan J ^a   Socié, Gerard ^a   Willemze, Roel ^a   Ifrah, Norbert ^a   Greinix, Hildegard T ^a   Blaise, Didier ^a   Deconinck, Eric ^a   Ferrant, Augustin ^a   Schattenberg, Anton ^a   Harousseau, Jean Luc ^a   Sureda, Anna ^a   Schmitz, Norbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 79951926833     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.3607     Document Type: Article

References (40)

1. Herrinton LJ, Weiss NS: Incidence of Waldenstrom's macroglobulinemia. Blood 82:3148-3150, 1993 (Pubitemid 23334943)
2. Groves FD, Travis LB, Devesa SS, et al: Waldenstrom's macroglobulinemia: Incidence patterns in the United States, 1988-1994. Cancer 82: 1078-1081, 1998
3. Vijay A, Gertz MA: Waldenstrom macroglobulinemia. Blood 109:5096-5103, 2007
4. Owen RG, Treon SP, Al-Katib A, et al: Clinico-pathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003 (Pubitemid 36506291)
5. Swerdlow SH, Neal C: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
6. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000 (Pubitemid 30036355)
7. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al: Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23:1564-1577, 2005
8. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116-120, 2003 (Pubitemid 36506292)
9. Morel P, Monconduit M, Jacomy D, et al: Patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000
10. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113:4163-4170, 2009
11. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases. J Clin Oncol 11:1553-1558, 1993 (Pubitemid 23228262)
12. Merlini G, Baldini L, Broglia C, et al: Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30:211-215, 2003 (Pubitemid 36506311)
13. Ghobrial IM, Fonseca R, Gertz MA, et al: Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 133:158-164, 2006
14. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945, 1994
15. Dhodapkar MV, Hoering A, Gertz MA, et al: Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113:793-796, 2009
16. Leblond V, Lévy V, Maloisel F, et al: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamidedoxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644, 2001
17. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004
18. Annibali O, Petrucci MT, Martini V, et al: Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: Results and cost analysis. Cancer 103:582-587, 2005
19. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247, 2003 (Pubitemid 36506318)
20. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25:3344-3349, 2007 (Pubitemid 47325621)
21. Buske C, Hoster E, Dreyling M, et al: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:153-161, 2009
22. Treon SP, Branagan AR, Ioakimidis L, et al: Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 113:3673-3678, 2009
23. Treon SP, Soumerai JD, Branagan AR, et al: Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112:4452-4457, 2008
24. Treon SP, Ioakimidis L, Soumerai JD, et al: Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol, 27:3830-3835, 2009
25. Anagnostopoulos A, Hari PN, Pérez WS, et al: Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 12:845-854, 2006 (Pubitemid 44096738)
26. Dreger P, Schmitz N: Autologous stem cell transplantation as part of first-line treatment of Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 13:623-624, 2007 (Pubitemid 46585936)
27. Tournilhac O, Leblond V, Tabrizi R, et al: Transplantation in Waldenstrom's macroglobulinemia: The French experience. Semin Oncol 30:291-296, 2003 (Pubitemid 36506328)
28. Kyriakou C, Dea CCS: High-dose therapy and autologous stem cell transplantation (ASCT) in Waldenstrom macroglobulinemia (WM): The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:2227-2232, 2010
29. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442-3446, 2006
30. Kimby E, Treon SP, Anagnostopoulos A, et al: Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 6:380-383, 2006
31. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
32. Klein JP, Rizzo JD, Zhang MJ, et al: Statistical methods for the analysis and presentation of the results of bone marrow transplants. I: Unadjusted analysis. Bone Marrow Transplant 28:909-915, 2001 (Pubitemid 33130231)
33. Klein JP, Rizzo JD, Zhang MJ, et al: Statistical methods for the analysis and presentation of the results of bone marrow transplants. II: Regression modeling. Bone Marrow Transplant 28:1001-1011, 2001 (Pubitemid 34030645)
34. Dreger P, Stilgenbauer S: Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom's macroglobulinemia. Presented at the Fourth International Workshop for Waldenstrom's Macroglobulinemia, Paris, France, October 7-10, 2004 (abstr 45)
35. Maloney DG: Evidence for GVWM following miniallo in WM. Presented at the Fifth International Workshop for Waldenstrom's Macroglobulinemia, Stockholm, Sweden, October 15-19, 2008 (abstr 147)
36. Michallet M, Bilger K, Garban F, et al: Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19:3340-3349, 2001 (Pubitemid 32642186)
37. Khouri IF, Saliba RM, Giralt SA, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001
38. Morris EC, Mackinnon S: Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. Best Pract Res Clin Haematol 18:129-142, 2005 (Pubitemid 40197870)
39. Rodriguez R, Nademanee A, Ruel N, et al: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 12:1326-1334, 2006 (Pubitemid 44858267)
40. Martino R, Iacobelli S, Brand R, et al: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846, 2006 (Pubitemid 44154615)